Vaccine-type oral HPV infection has declined among unvaccinated men.
Rates of human papillomavirus (HPV)–related oropharyngeal cancer have been rising among U.S. men, and the role of HPV immunization in reversing that trend is unclear, especially as immunization for men has only been recommended since 2011. To examine whether herd protection is present, investigators analyzed trends in oral HPV infection among unvaccinated men and women (age range, 18–59) from 2009 through 2016.
Among unvaccinated men, prevalence of vaccine-type (HPV-16, 18, 6, and 11) oral HPV fell from 2.7% in 2009–2010 to 1.6% in 2015–2016 (P=0.009). In contrast, prevalence of HPV types not included in the vaccine remained constant. Among unvaccinated women, prevalence of vaccine-type HPV was consistently about 0.6%.
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)